CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2020 Earnings Conference Call August 6, 2020 5:30 PM ET Company Participants Christopher Keenan – Vice President of Investor Relations Sean McCarthy – President, Chief Executive Officer and Chairman Carlos Campoy – Senior Vice President and Chief Financial Officer Conference Call Participants Waleed – Barclays Etzer Darout – Guggenheim Securities Terence Flynn – Goldman Sachs Biren Amin – Jefferies Mara Goldstein – Mizuho Mohit Bansal – Citi Joe Catanzaro – Piper S ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 CytomX Therapeutics, Inc. (Exact name of Registrant as Specified in its Charter) Delaware 27-3521219 (State or other jurisdiction of incorporation or organiz ...

REIMAGINING THERAPEUTIC ANTIBODIES FOR THE TREATMENT OF CANCER Goldman Sachs 41st Annual Global Healthcare Conference JUNE 10, 2020 © 2020 CytomX Therapeutics, Inc. 1 Forward Looking Statement This presentation may contain projections and other forward-looking statements regarding future events. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, technology platform, development strategy, prospective products ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q1 2020 Earnings Conference Call May 7, 2020 5:00 PM ET Company Participants Christopher Keenan - VP, IR Sean McCarthy - President, CEO, and Chairman Carlos Campoy - SVP and CFO Conference Call Participants Christopher Marai - Nomura Instinet Terence Flynn - Goldman Sachs Robert Burns - H.C. Wainwright Boris Peaker - Cowen Mara Goldstein - Mizuho Etzer Darout - Guggenheim Securities Joseph Catanzaro - Piper Sandler Mohit Bansal - Citigroup Biren Amin - Jefferies Opera ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 | --- | --- | --- | |---------------------------------------------------------------------------------------|----------------------------------------------- ...

REIMAGINING THERAPEUTIC ANTIBODIES FOR THE TREATMENT OF CANCER Cowen and Company 40th Annual Health Care Conference MARCH 2020 © 2020 CytomX Therapeutics, Inc. Forward Looking Statement This presentation may contain projections and other forward-looking statements regarding future events. All statements other than statements of historical facts contained in this presentation, including statements regarding our future financial condition, technology platform, development strategy, prospective products, precl ...

CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q4 2019 Results Earnings Conference Call February 27, 2020 5:00 PM ET Company Participants Christopher Keenan - VP, IR Sean McCarthy - President and CEO, and Chairman Amy Peterson - EVP and Chief Development Officer Robin Knifsend - VP, Finance Conference Call Participants Christopher Marai - Nomura Instinet Mara Goldstein - Mizuho Securities Robert Burns - H.C. Wainwright Etzer Darout - Guggenheim Biren Amin - Jefferies Joe Catanzaro - Piper Sandler Varun Kumar - Can ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |---------------------------------------------------------------------------------------------------|------------------------------------------------------------------------- ...

Financial Data and Key Metrics Changes - The company ended Q3 2019 with cash, cash equivalents, and investments totaling $325.7 million, down from $436.1 million as of December 31, 2018, and $349.1 million as of June 30, 2019 [38] - Research and development expenses were $28 million for the quarter, compared to $27.5 million in the corresponding period in 2018, reflecting an increase in personnel-related expenses and clinical trial activities [39] - General and administrative expenses were $8.5 million, up from $8.1 million in the same period in 2018 [40] - Revenue for the quarter was $10.7 million, down from $12.5 million in the corresponding period in 2018, primarily due to a decrease in revenue under the CD71 agreement with AbbVie [40] Business Line Data and Key Metrics Changes - The lead clinical asset CX-072 has shown activity as a monotherapy in multiple tumor types, with a recent Phase 1 study showing a 19% overall response rate in a heavily pretreated patient population [23][25] - CX-2009, a Probody drug conjugate targeting CD166, is in the dose refinement stage after completing dose escalation, with next steps anticipated by the end of 2019 [21] Market Data and Key Metrics Changes - The company is focusing on the unmet medical need in advanced melanoma, where approximately 40% of patients do not respond to initial PD inhibition, and over 25% discontinue treatment due to toxicity [28][29] - The combination of CX-072 with ipilimumab is expected to improve outcomes in patients with high unmet medical needs, particularly in relapsed or refractory melanoma [30] Company Strategy and Development Direction - CytomX aims to transition from a research-focused platform company to an integrated R&D organization with multiple emerging product candidates [10] - The company is leveraging its Probody platform to create differentiated anti-cancer therapies, with a focus on targeting therapeutic antibodies into disease tissue [8][9] - The partnership with Bristol Myers Squibb (BMS) is advancing with a randomized Phase 2a expansion cohort for a Probody version of ipilimumab, which could enhance the therapeutic index [32][34] - The collaboration with AbbVie continues to progress with CX-2029, a Probody drug conjugate targeting CD71, with co-development and profit-sharing rights retained by CytomX [36] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of CX-072 in combination therapies, particularly in melanoma, and highlighted the importance of addressing the unmet needs in this area [30][31] - The company anticipates a data-rich 2020, with additional pipeline guidance expected before year-end [41][79] Other Important Information - The appointment of Dr. Amy Peterson as Chief Development Officer is expected to enhance the company's clinical development strategies [7][30] - The company is focused on advancing its clinical pipeline while exploring the full potential of its Probody platform [41] Q&A Session Summary Question: What is the gating factor for CX-2009? - The company is focusing on dose refinements and understanding the relationship between ocular prophylaxis and patient duration on drugs, with an update expected by year-end [43] Question: What response rate is expected for CX-072 in refractory melanoma? - The company is optimistic based on previous data showing a 19% response rate in a heavily pretreated population but is not providing specific guidance at this stage [45] Question: How is the company approaching triple-negative breast cancer? - The company sees potential for CX-072 as a combination partner for other molecules and is open to partnerships at the right time [47] Question: What is the status of the Amgen partnership? - The Amgen partnership is currently focused on preclinical research, with no specific updates at this time [51] Question: What is the expected timeline for data from the AbbVie CD71 program? - No specific timing for updates on the CD71 program has been provided [51] Question: What is considered clinical success for CX-072? - The company is not setting specific goals but is optimistic based on previous response rates observed [57] Question: What is the regulatory strategy for advancing CX-072? - The regulatory path will depend on the activity observed in the ongoing studies, with a focus on creativity in collaboration with health authorities [63] Question: What percentage of first-line melanoma patients receive combination therapy? - Treatment patterns vary, with community physicians often focusing on minimizing side effects and may withhold CTLA4 agents until necessary [77]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-37587 | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------------------|----------- ...